TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 342623

Group type: EXPERIMENTAL
Intervention: Bivalent A/Victoria/75-A/New Jersey/76 influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent B/Hong Kong/72 influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent A/Victoria/75-A/New Jersey/76 and Monovalent B/Hong Kong/72 influenza vaccines (given together)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 0
Study: 30784893

Group type: EXPERIMENTAL
Intervention: FAI group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27589995

Group type: EXPERIMENTAL
Intervention: L-serine (0.5, 2.5, 7.5, or 15 g/dose, twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched historical placebo controls from five previous ALS therapeutic trials
Number of subjects: 20
Study: 26135703

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 22345689

Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational program (EP) in cardiovascular prevention (CVP) for children
Number of subjects: 197

Group type: COMPARATOR
Intervention: Written educational material (EM) for parents about healthy lifestyle (Control)
Number of subjects: 197
Study: 16778262

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP for 4 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 68
Study: 15290417

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg oral premedication 1 hour before induction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no atenolol)
Number of subjects: 24
Study: 11008910

Group type: EXPERIMENTAL
Intervention: Multiple outcall intervention
Number of subjects: 983

Group type: COMPARATOR
Intervention: Single outcall intervention
Number of subjects: 983

Group type: COMPARATOR
Intervention: Health survey only (control)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Advance card + single outcall
Number of subjects: 983
Study: 9360203

Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg q6h)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1490692

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study: 2986300

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol with hydrochlorothiazide
Number of subjects: 19
Study: 30892844

Group type: EXPERIMENTAL
Intervention: Dance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 28012564

Group type: EXPERIMENTAL
Intervention: Methotrexate at a starting dose of 17.5 mg/week for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Number of subjects: 120
Study: 27481744

Group type: EXPERIMENTAL
Intervention: Hypocaloric enteral nutrition (15 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normocaloric enteral nutrition (25 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Number of subjects: 120
Study: 24816958

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) injection (20 U into internal anal sphincter)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream (thrice daily for 6 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) injection (20 U)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream
Number of subjects: 41
Study: 22879656

Group type: EXPERIMENTAL
Intervention: DEX 0.15 mg kg(‐1)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: DEX 0.5 mg kg(‐1)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 147
Study: 19662630

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-20 mg/day)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Antidepressant (ADT) monotherapy
Number of subjects: 722
Study: 17565929

Group type: EXPERIMENTAL
Intervention: Fixed combination latanoprost/timolol
Number of subjects: 1052
Study: 15155718

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 42
Study: 11593092

Group type: EXPERIMENTAL
Intervention: Moderate exercise (40-55% HRres)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Vigorous exercise (65-80% HRres)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (minimally supervised home-based exercise)
Number of subjects: 126
Study: 9638417

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg peroral
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SMS 201-995 100 microgram subcutaneously
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Verapamil plus SMS 201-995
Number of subjects: 40
Study: 8135390

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 20
Study: 2554500

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin fraction CY 216
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study: 30907678

Group type: EXPERIMENTAL
Intervention: SMART intervention (delivered online or in-person)
Number of subjects: 50
Study: 28590828

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg qd
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg bid
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg qd
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 25425015

Group type: EXPERIMENTAL
Intervention: Lercanidipine hydrochloride
Number of subjects: 281

Group type: COMPARATOR
Intervention: Felodipine sustained-release tablets
Number of subjects: 281
Study: 24133618

Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy nutritional recommendation (HNR) diet
Number of subjects: 50
Study: 21681154

Group type: EXPERIMENTAL
Intervention: Weighted Rope Training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rope Training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 20031845

Group type: EXPERIMENTAL
Intervention: Multilevel, multicomponent intervention (interactive computerized hypertension education, home BP monitoring, monthly behavioral counseling)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multilevel, multicomponent intervention
Number of subjects: 30
Study: 16678643

Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d for up to 12 months
Number of subjects: 581

Group type: COMPARATOR
Intervention: Naproxen 750 mg/d for up to 12 months
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d
Number of subjects: 581

Group type: COMPARATOR
Intervention: Naproxen 750 mg/d
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 581
Study: 15379423

Group type: EXPERIMENTAL
Intervention: FAST1-MRI
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine MRI
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ectopic hyperintense signal
Number of subjects: 48
Study: 11179329

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy U.S. controls
Number of subjects: 0
Study: 9412611

Group type: EXPERIMENTAL
Intervention: Lubeluzole (7.5 mg over 1 hour, followed by a continuous daily infusion of 10 mg for up to 5 days)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Lubeluzole
Number of subjects: 721
Study: 8504976

Group type: EXPERIMENTAL
Intervention: Enteric coated pancreatin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2894247

Group type: EXPERIMENTAL
Intervention: Isoproterenol injections
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cream containing colforsin (forskolin), aminophylline, and yohimbine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Yohimbine cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Colforsin cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aminophylline cream
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (injection or cream)
Number of subjects: 28
Study: 29465629

Group type: EXPERIMENTAL
Intervention: Titanium fasteners
Number of subjects: 73

Group type: COMPARATOR
Intervention: Hand-tied knots
Number of subjects: 73
Study: 27018897

Group type: EXPERIMENTAL
Intervention: Video Decision Aid + Health Coaching (DA+HC)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Video Decision Aid only (DA)
Number of subjects: 199
Study: 24059730

Group type: EXPERIMENTAL
Intervention: CAGT6 (six-session palmtop computer-assisted Group CBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: CBGT6 (six-session Group CBT without the computer)
Number of subjects: 34

Group type: COMPARATOR
Intervention: CBGT12 (typical 12-session Group CBT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CAGT6
Number of subjects: 34
Study: 22841478

Group type: EXPERIMENTAL
Intervention: 5 μg of virus protein per 0.5 mL formulation
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: 2.5 μg of virus protein per 0.5 mL formulation
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: 1.25 μg of virus protein per 0.5 mL formulation
Number of subjects: 370
Study: 20353659

Group type: EXPERIMENTAL
Intervention: e‐Nudge electronic reminders
Number of subjects: 38000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38000
Study: 18688013

Group type: EXPERIMENTAL
Intervention: 15 mg/h clazosentan
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: 1 mg/h clazosentan
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: 5 mg/h clazosentan
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 16187967

Group type: EXPERIMENTAL
Intervention: Sustained release isosorbide 5' mono-nitrate (ISMN) 120 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (TD-NTG) 15 mg 24 h(‐1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) 10 micromol l(‐1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nitroglycerine (NTG) 100 micromol l(‐1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: ADP (1 micromol l(‐1))
Number of subjects: 34
Study: 12773674

Group type: EXPERIMENTAL
Intervention: Rapid MR imaging
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional MR imaging
Number of subjects: 88
Study: 10950384

Group type: EXPERIMENTAL
Intervention: Model C (PVE corrected rCBF during rest)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Autoradiographic method (2D acquisition)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Autoradiographic method (3D acquisition)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Model C and D (activation response)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Model C (activation response)
Number of subjects: 8
Study: 8840095

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 10
Study: 1993133

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase 1.5 x 10(6) IU (n = 55)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo infusion (n = 26)
Number of subjects: 81
Study: 6687717

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study: 31985129

Group type: EXPERIMENTAL
Intervention: 4-week nurse-led transitional care intervention based on the Omaha System
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 88
Study: 31288213

Group type: EXPERIMENTAL
Intervention: BFR‐RT at 30% 1RM
Number of subjects: 28

Group type: COMPARATOR
Intervention: HL‐RT at 70% 1RM
Number of subjects: 28
Study: 28079606

Group type: EXPERIMENTAL
Intervention: Protocol-based care
Number of subjects: 628

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 628
Study: 25487798

Group type: EXPERIMENTAL
Intervention: GSK1322322 (oral-i.v. combination)
Number of subjects: 61

Group type: COMPARATOR
Intervention: GSK1322322 (i.v. only)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24052491

Group type: EXPERIMENTAL
Intervention: High-dose, short-duration dietary oral supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21636820

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 19151300

Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 66
Study: 16510634

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical and nonsurgical interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening (clinical examination or ultrasound)
Number of subjects: 0
Study: 11812666

Group type: EXPERIMENTAL
Intervention: Digitalis administration in supine position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Digitalis administration in supine position with leg elevation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Leg elevation in pre-digitalis state (normal ventricular function)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Leg elevation in LVD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Digitalis administration in LVD patients
Number of subjects: 30
Study: 10409470

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg intravenously pre-operatively
Number of subjects: 12

Group type: COMPARATOR
Intervention: No pamidronate (control group)
Number of subjects: 12
Study: 7582139

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mail follow-up
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preference for follow-up
Number of subjects: 100
Study: 2147517

Group type: EXPERIMENTAL
Intervention: paroxetine (30 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: amitriptyline (150 mg/day)
Number of subjects: 40
Study: 390784

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-dose steroids
Number of subjects: 20
Study: 6614412

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study: 30145124

Group type: EXPERIMENTAL
Intervention: MRI-positive group (n=13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: MRI-negative group (n=15)
Number of subjects: 28
Study: 29290087

Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy with mild hydronephrosis (Group C)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Standard procedure shock wave lithotripsy (Group A)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Shock wave lithotripsy in prone position (Group B)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 371
Study: 27521810

Group type: EXPERIMENTAL
Intervention: Ibudilast (100mg/day)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 25326208

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy (HA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short format of health scenarios
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long format of health scenarios
Number of subjects: 0
Study: 23106853

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U)
Number of subjects: 621
Study: 20308718

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Propranolol (PPL)
Number of subjects: 75
Study: 17631071

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 501
Study: 16172700

Group type: EXPERIMENTAL
Intervention: Fluoxetine (0.25 to 0.50 mg/kg for three months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12441944

Group type: EXPERIMENTAL
Intervention: Noncontact laser therapy
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Transurethral prostate resection
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 340
Study: 10096264

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril (standard treatment for high blood pressure)
Number of subjects: 20
Study: 7577202

Group type: EXPERIMENTAL
Intervention: Daunorubicin and cytarabine with granulocyte colony-stimulating factor (G-CSF) as supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine without granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study: 2013680

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with a maintenance dose of 1.94 micrograms of antigen E (Amb a I) for 8 months (total dose equivalent to 24 micrograms of antigen E)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6756509

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen + Immunotherapy
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: BCG Immunotherapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 318
Study: 31924377

Group type: EXPERIMENTAL
Intervention: Macrolide-resistant Mycoplasma pneumoniae
Number of subjects: 826

Group type: COMPARATOR
Intervention: Macrolide-susceptible Mycoplasma pneumoniae
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: MLVA 4-5-7-2
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: MLVA 4-5-7-3
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: MLVA 1-5-6-2
Number of subjects: 826
Study: 30563829

Group type: EXPERIMENTAL
Intervention: Rapamycin (3 mg orally daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29218705

Group type: EXPERIMENTAL
Intervention: Rapid AED taper (30% to 50% dose reduction)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Slow AED taper (15% to <30% dose reduction)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Rapid AED taper
Number of subjects: 140

Group type: COMPARATOR
Intervention: Slow AED taper
Number of subjects: 140
Study: 27333978

Group type: EXPERIMENTAL
Intervention: CRT with negative ΔQRS (persistent electrical dyssynchrony)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CRT with persistent electrical dyssynchrony (ED)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CRT with negative ΔQRS
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CRT with QRS prolongation
Number of subjects: 95
Study: 24754230

Group type: EXPERIMENTAL
Intervention: Biological attributions
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Personal responsibility attributions
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Food environment attributions
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Food environment information (Study 2)
Number of subjects: 220
Study: 21997197

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 2 injections of 1.25 mg with 6-week intervals
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab combined with triamcinolone (IVB/IVT) - 1.25 mg of IVB with 2 mg of IVT
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) - 2 mg of IVT
Number of subjects: 105
Study: 19648218

Group type: EXPERIMENTAL
Intervention: R231857
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: R231857 with scopolamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 42
Study: 17665231

Group type: EXPERIMENTAL
Intervention: Amphotericin B (monotherapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Fluconazole (monotherapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Flucytosine (monotherapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Itraconazole (monotherapy)
Number of subjects: 304
Study: 16224654

Group type: EXPERIMENTAL
Intervention: Laparoscopic extended right hemicolectomy plus lymphadenectomy with skeletonization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open extended right hemicolectomy plus lymphadenectomy with skeletonization
Number of subjects: 30
Study: 12098725

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 315

Group type: COMPARATOR
Intervention: Delayed antibiotics
Number of subjects: 315
Study: 10463975

Group type: EXPERIMENTAL
Intervention: Hepatic arterial chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin
Number of subjects: 31